Login to Your Account



Overall Survival Miss

Threshold's Stock Slammed on Pancreatic Cancer Drug Data

By Catherine Shaffer
Staff Writer

Monday, September 17, 2012
Threshold Pharmaceuticals Inc. saw its shares fall 19.7 percent Monday, following release of an update to its Phase IIb trial of TH-302 in pancreatic cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription